论文部分内容阅读
目的:探讨EZH2与宫颈癌临床病理特征及预后的关系。方法:采用免疫组化法分别检测20例正常宫颈组织、20例宫颈上皮内瘤变(CIN)、101例宫颈癌中EZH2、Ki-67蛋白的表达,并分析EZH2与Ki-67、临床病理特征及预后的相关性。结果:EZH2在正常宫颈组织、CIN、宫颈癌的阳性表达率分别为10%(2/20)、60%(12/20)、68.3%(69/101),差异有统计学意义(P<0.05)。Ki-67蛋白在正常宫颈组织、CIN、宫颈癌的阳性表达率分别为5%(1/20)、50%(10/20)、57.4%(58/101),且与EZH2表达呈正相关(r=0.440,P<0.05)。EZH2在宫颈癌组织中的表达与临床分期、肿瘤分化程度、间质浸润深度、淋巴结转移密切相关(P均<0.05)。在宫颈癌患者中,EZH2阳性组较阴性组平均生存时间明显缩短(42.3个月vs 52.3个月,P=0.003)。COX比例风险模型多因素分析结果显示,EZH2是宫颈癌的独立预后因素(RR:1.595,95%CI:1.188～2.827,P=0.044)。结论:EZH2异常表达与宫颈癌临床病理特征及预后密切相关,提示EZH2可能成为预测肿瘤预后的标记物及潜在分子治疗靶点。
Objective: To investigate the relationship between EZH2 and clinicopathological characteristics and prognosis of cervical cancer. Methods: The expression of EZH2 and Ki-67 in 20 cases of normal cervical tissue, 20 cases of cervical intraepithelial neoplasia (CIN) and 101 cases of cervical cancer were detected by immunohistochemical method. The relationship between EZH2 and Ki-67, clinical pathology Correlation of features and prognosis. Results: The positive rates of EZH2 in normal cervical tissue, CIN and cervical cancer were 10% (2/20), 60% (12/20) and 68.3% (69/101), respectively, with significant difference (P < 0.05). The positive rates of Ki-67 protein in normal cervical tissue, CIN and cervical cancer were 5% (1/20), 50% (10/20) and 57.4% (58/101), respectively, which were positively correlated with the expression of EZH2 r = 0.440, P <0.05). The expression of EZH2 in cervical cancer was closely related to clinical stage, tumor differentiation, depth of interstitial infiltration and lymph node metastasis (all P <0.05). In cervical cancer patients, the average survival time of EZH2-positive group was significantly shorter than that of the negative group (42.3 months vs 52.3 months, P = 0.003). Multivariate analysis showed that EZH2 was an independent prognostic factor for cervical cancer (RR: 1.595, 95% CI: 1.188-2.827, P = 0.044). Conclusion: The abnormal expression of EZH2 is closely related to the clinicopathological features and prognosis of cervical cancer, suggesting that EZH2 might be a potential marker of tumor prognosis and a potential molecular target for therapy.